Luveris Market Report 2026

Luveris Market Overview

• The Luveris market growth in the historic period has been driven by increasing infertility prevalence, expansion of IVF clinics globally • Market expansion is supported by increasing maternal age trends, rising investments in fertility clinics • Growth Driver: Impact Of Rising Infertility Rates On The Market Growth • Market Trend: Strategic Investments In Research And Development To Drive Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Luveris Market?

Luveris (lutropin alfa) is a synthetic form of luteinizing hormone used in fertility treatments for women with severe LH deficiency or undergoing assisted reproductive technologies like in vitro fertilization (IVF). It works by mimicking natural LH to stimulate ovarian follicle development and ovulation, often in combination with follicle-stimulating hormone (FSH). Administered via subcutaneous injection, Luveris plays a vital role in helping women achieve successful ovulation and pregnancy outcomes under the supervision of a healthcare provider. The main formulations of luveris are injectable formulations (intravenous) and pre-filled syringes. The injectable formulation of Luveris (lutropin alfa) is administered directly into the bloodstream through an intravenous (IV) injection. It is used for the treatment of hypogonadotropic hypogonadism, ovulation induction, and assisted reproductive technology and has both subcutaneous injection and intramuscular injection routes of administration. It is used by various types of patient demographics, such as adult female patients, adult male patients, and couples undergoing fertility treatments. It is used by hospitals, fertility clinics, specialty pharmacies, and home healthcare providers.

What Is The Luveris Market Growth Forecast?

The growth in the forecast period can be attributed to increasing maternal age trends, rising investments in fertility clinics, growing adoption of personalized reproductive medicine, expansion of fertility preservation services, increasing demand for advanced hormonal therapies. Major trends in the forecast period include increasing adoption of hormone-based fertility therapies, rising use of assisted reproductive technologies, growing demand for personalized fertility treatment protocols, expansion of combination hormone therapies, enhanced focus on controlled ovulation induction.

Global Luveris Market Segmentation

1) By Formulation: Injectable Formulation (Intravenous), Pre-Filled Syringes 2) By Indication: Treatment Of Hypogonadotropic Hypogonadism, Ovulation Induction, Assisted Reproductive Technology 3) By Route of Administration: Subcutaneous Injection, Intramuscular Injection 4) By Patient Demographics: Adult Female Patients, Adult Male Patients, Couples Undergoing Fertility Treatments 5) By End User: Hospitals, Fertility Clinics, Specialty Pharmacies, Home Healthcare Providers

What Are The Drivers Of The Luveris Market?

The rising infertility rates are expected to propel the growth of the luveris market going forward. Infertility rates refer to the percentage of couples or individuals who are unable to conceive after a certain period of trying, typically measured over a year of unprotected intercourse. Increasing infertility rates are attributed to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris (lutropin alfa) is used to treat infertility in women with low levels of luteinizing hormone (LH) by stimulating ovulation and promoting the development of eggs in the ovaries. For instance, in July 2023, according to the Human Fertilisation and Embryology Authority, a UK-based regulator of fertility treatment and research, the number of patients undergoing in vitro fertilisation (IVF) at HFEA-licensed fertility centres rose to 52,400 in 2023, up from previous years, while donor insemination (DI) treatments resulted in around 820 births, up from fewer births in earlier years. Therefore, the rising infertility rates will drive the growth of the luveris industry. The expanding healthcare infrastructure is expected to fuel the growth of the luveris market going forward. Healthcare infrastructure includes hospitals, clinics, medical equipment, healthcare workers, and other organizational and physical structures, buildings, resources, and systems needed to provide healthcare services. Healthcare infrastructure is expanding to meet the growing demand for medical services driven by increasing populations, aging demographics, advancements in healthcare technology, and the need for better accessibility and quality of care. The expansion of healthcare infrastructure positively impacts luveris by improving access to advanced fertility treatments and supporting the growth of specialized medical centers that utilize innovative therapies for infertility. For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the UK government announced that it will invest more than $25.33 billion (£20 billion) in the New Hospital Programme, which aims to create 40 new hospitals in England by 2030. Therefore, the expanding healthcare infrastructure will drive the growth of the luveris industry.

Key Players In The Global Luveris Market

Major companies operating in the luveris market are Merck KGaA

Global Luveris Market Trends and Insights

The key trend in the luveris market is adopting a strategic investment approach for the development and manufacture of novel medicines. Strategic investments are investments made with the goal of achieving long-term business objectives, such as gaining a competitive advantage, expanding market share, or enhancing operational capabilities. For instance, in April 2024, Merck KGaA, a Germany-based science and technology company, invested $316 million (€300 million) in a brand-new research facility at its international headquarters in Darmstadt, Germany. The advanced research center will focus on developing solutions for manufacturing antibodies, mRNA applications, and other products essential for biotechnological production within Merck's Life Science business sector. This center will consolidate research on key technologies, including raw materials and processes for the production of antibodies, recombinant proteins, and viral vectors. Additionally, the center will advance research in cell culture media, pharmaceutical formulation and purification aids, digital reference materials, and the further development of analytical chromatography, a method for separating, identifying, and quantifying chemical substances. Research along the mRNA value chain will also be conducted at the new facility.

Regional Insights

North America was the largest region in the luveris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Luveris Market?

The luveris market consists of sales of follitropin alfa, menotropins, progesterone and follitropin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Luveris Market Report 2026?

The luveris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the luveris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.